Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | KLK7 | P49862 | 4/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22433332 | 0.80 | KLK7 (0.54) | PPARGPPARAKLK7KLK5CTSS | |
| SCHEMBL22433331 | 0.80 | KLK7 (0.54) | PPARGPPARAKLK7KLK5CTSS | |
| SCHEMBL18306699 | 0.78 | CTSK (0.48) | KLK7KLK5CTSKCTSSATM | |
| SCHEMBL3285441 | 0.77 | AAK1 (0.39) | PPARGPPARAPPARDCTSKCTSS | |
| SCHEMBL7438422 | 0.76 | TRPA1 (0.57) | PPARGPPARAPPARDKLK5CTSK | |
| SCHEMBL8283003 | 0.76 | TRPA1 (0.57) | PPARGPPARAPPARDKLK5CTSK | |
| SCHEMBL23619006 | 0.76 | PPARA (0.48) | PPARGPPARAPPARDCTSKCTSS | |
| SCHEMBL15432503 | 0.76 | PPARA (0.48) | PPARGPPARAPPARDCTSKCTSS | |
| SCHEMBL3740636 | 0.76 | PPARA (0.48) | PPARGPPARAPPARDCTSKCTSS | |
| SCHEMBL1104909 | 0.75 | ATM (0.54) | PPARGPPARAKLK7KLK5CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617276-B2 | Compounds and methods for treating AIDS and HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617276-B2 | Compounds and methods for treating AIDS and HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150111962-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| US-20150111962-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| US-8921349-B2 | Compounds and methods for treating AIDS and HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921349-B2 | Compounds and methods for treating AIDS and HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2429290-B1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20120059161-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059161-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059161-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | CTSS, DNPEP, PEPD | PPARG 4233/4885PPARA 4246/4885PPARD 4642/4885 |
| US-20150111962-A1 | COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS | CTSS, DNPEP, PEPD | PPARG 4233/4885PPARA 4246/4885PPARD 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.